Janssen Immunology has expanded our pipeline and portfolio beyond anti-cytokine antibodies, to include the development of novel therapeutics that modify the autoantibody pathway, which has important potential in multiple immune-mediated diseases.
An autoantibody is a type of protein produced by the immune system that binds to an individual’s own tissues or organs. Many immune-mediated diseases are characterized by autoantibodies that bind to their target and form immune complexes (ICs), which recruit and activate immune cells, leading to progressive tissue inflammation and damage. Because few agents exist that disrupt these abnormal immune processes, we are committed to pioneering therapeutics for patients with autoantibody-driven diseases.
Our research has the potential to deliver on the promise of addressing antibody-associated diseases. In our continued commitment, we will build the rationale for new therapies that offer the promise of revolutionized care for patients.
Eggert M, Zettl, et al. Autoantibodies in autoimmune diseases. Curr Pharm Des. 2010 May;16(14):1634-43. DOI: 10.2174/138161210791164144. PMID: 20196735.
Ludwig Ralf J., et al. Mechanisms of Autoantibody-Induced Pathology. Frontiers in Immunology. 2017. 603. DOI: 10.3389/fimmu.2017.00603. ISSN=1664-3224.